AstraZeneca’s move to upgrade its U.S. listing could draw liquidity from London, sparking concerns of a trend among large companies. The drugmaker plans to offer shares directly on the NYSE, citing U.S. shareholder importance and revenue growth projection. Analysts and policymakers express relief over the decision to retain London listing.

AstraZeneca’s decision to stay listed in the UK brings clarity and confidence in the economy, according to a government spokesperson. With no current plans to scrap its London listing, some foresee potential risks of trading shifting to the U.S. and other firms following suit. Large UK-listed companies with significant U.S. investor bases may consider implications.

London-listed firms face pressure to consider listing swaps due to valuation gaps and stronger foreign market performance. AstraZeneca’s size may outgrow London’s market, prompting calls for listing shifts. Wise plans to switch to NY, while others like Rio Tinto and Glencore resist. The risk of a future full exit from the UK is noted.

AstraZeneca’s recommitment to London is seen as a positive in the short term, according to investment professionals. The London Stock Exchange emphasizes the company’s ongoing commitment to the UK market. Despite the move, the appeal of London’s capital markets remains strong, with advocates citing benefits for global investors.

AstraZeneca Chair highlights New York’s advantages in a letter to shareholders, praising the U.S. as a hub for biopharma innovation. Despite the move, confidence in London’s appeal remains high, with experts emphasizing benefits for global investors and the company. The decision aims to provide easier access to shares while retaining London’s benefits.

Read more at Yahoo Finance: Analysis-AstraZeneca’s US listing may pull other firms from London in its wake